ReviewMicrobial biotechnology2012
Design of therapeutic vaccines: hepatitis B as an example.
Review in Microbial biotechnology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 43 citations in OpenAlex.
- A VLP vaccine platform comprising the core protein of hepatitis B virus with N-terminal antigen capture.International journal of biological macromolecules · 2025Article
- mRNA-LNP vaccine strategies: Effects of adjuvants on non-parenchymal liver cells and tolerance.Molecular therapy. Methods & clinical development · 2025Article
- HBV Vaccines: Advances and Development.Vaccines · 2023Review
- Efficient stabilization of therapeutic hepatitis B vaccine components by amino-acid formulation maintains its potential to break immune tolerance.JHEP reports : innovation in hepatology · 2023Article
- Modified Alphavirus-Vesiculovirus Hybrid Vaccine Vectors for Homologous Prime-Boost Immunotherapy of Chronic Hepatitis B.Vaccines · 2020Article
- Synthesis and Assembly of Hepatitis B Virus-Like Particles in aFrontiers in bioengineering and biotechnology · 2020Article
- Hepatitis B Vaccine and Immunoglobulin: Key Concepts.Journal of clinical and translational hepatology · 2019Review
- A Highly Attenuated Vesicular Stomatitis Virus-Based Vaccine Platform Controls Hepatitis B Virus Replication in Mouse Models of Hepatitis B.Journal of virology · 2019Article
- Drugs in Development for Hepatitis B.Drugs · 2017Review
- Research progress of therapeutic vaccines for treating chronic hepatitis B.Human vaccines & immunotherapeutics · 2017Review
- Treatment of hepatitis B virus: an update.Future microbiology · 2016Review
- Current progress in the development of therapeutic vaccines for chronic hepatitis B virus infection.Iranian journal of basic medical sciences · 2016Review
- An autophagosome-based therapeutic vaccine for HBV infection: a preclinical evaluation.Journal of translational medicine · 2014Article
- Strategies to eliminate HBV infection.Future virology · 2014Article
- Living in the liver: hepatic infections.Nature reviews. Immunology · 2012Review
- Management of the Hepatitis B Virus/HIV-Coinfected Patient.Topics in antiviral medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Therapeutic vaccines are currently developed for chronic viral infections, such as human papillomavirus (HPV), human immunodeficiency virus (HIV), herpesvirus and hepatitis B (HBV) and C (HCV) virus infections. As an alternative to antiviral treatment or to support only partially effective therapy a therapeutic vaccine shall activate the patient's immune system to fight and finally control or ideally even eliminate the virus. Whereas the success of prophylactic vaccination is based on rapid neutralization of the invading pathogen by antibodies, virus control and elimination of infected cells require T cells. Therefore, induction of a multi-specific and multifunctional T-cell response against key viral antigens is a paradigm of therapeutic vaccination--besides activation of a humoral immune response to limit virus spread. In this review, we describe options to develop a therapeutic vaccine for chronic viral infections using HBV as a promising example.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.